PI5P migrates out of the PIP shadow

In a recent study published in EMBO reports, the group of Jorgen Wesche identified a new role for PI5P as a positive regulator of cell migration, most likely by facilitating actin cytoskeletal rearrangements.EMBO reports (2013) 14 1, 57–64 doi:10.1038/embor.2012.183The dynamic nature of membrane phospholipid turnover was first described by Hokin and Hokin during their studies on exocrine tissue stimulation (reviewed in [1]). Subsequently, phosphatidylinositol (PI) and its phosphorylated products, called phosphoinositides, were shown to have a fundamental role in regulating membrane–cytosol interfaces in several contexts, including regulating signal transduction, membrane traffic and permeability, the cytoskeleton, nuclear events and transport [1]. Seven phosphoinositides have been identified and are defined by the phosphorylation state of the inositol headgroup at the 3′-, 4′- and 5′-position, which is regulated reversibly by several lipid kinases and phosphatases [1]. Of the seven lipid species, phosphatidylinositol-5-phosphate (PI5P) was most recently discovered by the Cantley group and remains the most enigmatic of the phosphoinositide family [2]. PI5P levels have been shown to change in response to stimuli such as thrombin, histamine, insulin and oxidative stress, and have been suggested to regulate various processes, including signalling pathways, nuclear functions, vesicular transport and cytoskeletal organization [3,4,5]. In a recent issue of EMBO reports, Oppelt and colleagues identified a new role for PI5P as a positive regulator of cell migration probably by facilitating actin cytoskeletal rearrangements [6].Unlike other phosphoinositides (PI3P and PI4P) that can be produced through the direct phosphorylation of PI, there is no evidence that PI5P can be produced through the direct in vivo phosphorylation of PI. Instead, PI4P 5-kinases generate PI(4,5)P₂ from PI4P and PIKfyve generates PI(3,5)P₂ from PI3P, and the products PI(3,5)P₂ and PI(4,5)P₂ are dephosphorylated by myotubularin-related proteins (that is, MTMR3) and inositol 4-phosphatases (PI(4,5)P₂ phosphatases type I and II), respectively, to produce PI5P (Fig 1). Recent in vivo evidence indicates that the PIKfyve–MTMR pathway is responsible for most PI5P production [7]. The study from the Wesche lab shows that production of PI5P through the MTMR3 pathway is important for cell migration [6]. After initially observing that depletion of the class III PI(3)K Vps34 and its lipid product, PI3P, impairs cell migration, the authors performed a small interfering RNA (siRNA) screen to identify FYVE or PX-domain-containing PI3P effectors that regulate this process. In addition to factors already known to promote migration—for example, Cdc42, FGD1, FGD2 and Hrs—PIKfyve and MTMR3 were identified as new candidates. PIKfyve has a PI3P-binding FYVE domain and, as mentioned above, synthesizes PI(3,5)P₂, whilst MTMR3, a member of the myotubularin family containing a PI3P-binding PH-GRAM domain, is a phosphatase that dephosphorylates PI(3,5)P₂ to PI5P. Cells depleted of PIKfyve or MTMR3 showed impaired cell polarization and defects in orienting actin filaments and the Golgi complex towards the growth factor stimulus. In addition, siRNA experiments and pharmacological inhibition of PIKfyve decreased migration velocity and persistence. These findings were confirmed in vivo when ablation of MTMR3 in border cells inhibited border cell migration in Drosophila during oogenesis. Taken together, the authors demonstrate that the lipid enzymes Vps34, PIKfyve and MTMR3 regulate the PI3P–PI(3,5)P₂–PI5P phosphoinositide interconversion pathway that mediates cell migration [6].Open in a separate windowFigure 1Pathways of PI5P synthesis and turnover. Pathways demonstrated in vivo are shown in bold text and arrows, whereas in vitro, putative pathways are represented in italics and broken arrows. Thick arrows highlight the PI5P production pathway responsible for cell migration as reported in reference [6]. IpgD, invasion plasmid gene D; MTM, myotubularin; PI, phosphatidylinositol; PI(3)K, phosphoinositide 3-kinase; PI5P, phosphatidylinositol-5-phosphate; PIKfyve, phosphoinositide kinase, FYVE finger containing; PTPMP1, protein tyrosine phosphatase, mitochondrial 1.The low abundancy, dynamic turnover and tight spatial restriction of the phosphoinositides enable them to mediate acute responses within cells [1]. Part of the initial difficulty in identifying PI5P was due to the fact that it is the phosphoinositide of lowest abundance—approximately 1–2% of PI4P—and that earlier high-performance liquid chromatography (HPLC) techniques had erroneously measured PI5P as its PI4P isomer [8]. By using improved biochemical techniques, the authors measured phosphoinoside levels during cell migration and found specifically that levels of PI5P rise acutely in response to migratory stimulation by fibroblast growth factor 1 (FGF1). Cells treated with PIKfyve and MTMR3 siRNA failed to produce PI5P on FGF1 stimulation, again suggesting that PIKfyve and MTMR3 constitute the interconversion pathway responsible for the production of PI5P during migration. Importantly, Oppelt and colleagues showed convincingly that PI5P is a relevant signalling mediator of cell migration [6]—when exogenous PI5P was added to MTMR3 and PIKfyve siRNA-treated cells, migration was partly rescued. To further confirm this finding, the authors showed that overexpression of the Shigella flexneri virulence factor IpgD, a PI(4,5)P₂ 4-phosphatase that converts PI(4,5)P₂ to PI5P [9], and production of endogenous PI5P in MTMR3 siRNA-treated cells also rescue migration defects. In fact, this production of PI5P from PI(4,5)P₂ proved that PI5P is a relevant migratory signal and not merely an intermediate to the production of PI(4,5)P₂, which has been implicated previously in regulating actin dynamics and, by contrast, requires PI4P synthesis—another potential intermediate for its signalling effects [1]. Interestingly, manipulation of PI5P levels in control cells does not initiate cell migration in the absence of stimulation, suggesting that PI5P is not sufficient to promote migration; instead, the pathway works together with others to promote migration and there is an inhibitory regulatory pathway that acts downstream from PI5P. This clearly demonstrates that it is PI5P and not PI3P, PI(3,5)P₂ or PI(4,5)P₂ that regulates cell migration.Preliminary evidence from Oppelt and colleagues suggests that PI5P might help to regulate actin cytoskeletal remodelling during migration [6]. For instance, silencing of MTMR3 and PIKfyve resulted in actin fibres that are unable to orient properly and form knots when cell migration was stimulated. These findings complement previous work indicating that PI5P regulates cytoskeletal organization in other contexts. For instance, PI5P production in response to insulin stimulation or on overexpression of the bacterial virulence factor IpgD induces disassembly of actin stress fibres [9,10]. The molecular mechanisms underlying PI5P''s regulation of actin polymerization and disassembly remain unclear. Additionally, the subcellular location of PI5P production in response to these agonists remains largely undetermined; however, membrane fractionation and HPLC analysis has localized PI5P to the nucleus, endoplasmic reticulum, Golgi and plasma membrane under basal conditions [8]. Standard tools used to study phosphoinositide localization have yet to be developed for PI5P. PI5P-binding domains are beginning to be identified and include the PHD domain of ING2, and the PH domain of Dok proteins [4], but it will be important to develop PI5P probes as well as continue to identify additional effectors to better understand PI5P function.The PI5P field is at a naive, yet exciting, stage in which studies such as that of Oppelt and colleagues advance our understanding of PI5P multiple roles in cellular function. Although this study has concentrated largely on identifying Vps34, PIKfyve and MTMR3 in the production of PI5P in response to migration stimuli, it will be essential to explore how the activities of these enzymes are regulated. Moreover, the mechanism of PI5P catabolism in this context and others, as well as the precise molecular basis for PI5P actions in the cellular contexts, have to be further elucidated. Finally, the crosstalk between PI5P and other phosphoinositide-mediated signalling cascades, such as the PI(3,4,5)P₃–Akt pathway, will have to be closely examined in the context of cell migration, based on previous studies showing that PI5P is a positive regulator of class IA PI(3)Ks [3].     

The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease

Charcot-Marie-Tooth disease type 4B (CMT4B) is a severe, demyelinating peripheral neuropathy characterized by distinctive, focally folded myelin sheaths. CMT4B is caused by recessively inherited mutations in either myotubularin-related 2 (MTMR2) or MTMR13 (also called SET-binding factor 2). MTMR2 encodes a member of the myotubularin family of phosphoinositide-3-phosphatases, which dephosphorylate phosphatidylinositol 3-phosphate (PI(3)P) and bisphosphate PI(3,5)P2. MTMR13 encodes a large, uncharacterized member of the myotubularin family. The MTMR13 phosphatase domain is catalytically inactive because the essential Cys and Arg residues are absent. Given the genetic association of both MTMR2 and MTMR13 with CMT4B, we investigated the biochemical relationship between these two proteins. We found that the endogenous MTMR2 and MTMR13 proteins are associated in human embryonic kidney 293 cells. MTMR2-MTMR13 association is mediated by coiled-coil sequences present in each protein. We also examined the cellular localization of MTMR2 and MTMR13 using fluorescence microscopy and subcellular fractionation. We found that (i) MTMR13 is a predominantly membrane-associated protein; (ii) MTMR2 and MTMR13 cofractionate in both a light membrane fraction and a cytosolic fraction; and (iii) MTMR13 membrane association is mediated by the segment of the protein which contains the pseudophosphatase domain. This work, which describes the first cellular or biochemical investigation of the MTMR13 pseudophosphatase protein, suggests that MTMR13 functions in association with MTMR2. Loss of MTMR13 function in CMT4B2 patients may lead to alterations in MTMR2 function and subsequent alterations in 3-phosphoinositide signaling. Such a mechanism would explain the strikingly similar phenotypes of patients with recessive mutations in either MTMR2 or MTMR13.     

The CMT4B disease‐causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signalling

Charcot‐Marie‐Tooth disease type 4B is caused by mutations in the genes encoding either the lipid phosphatase myotubularin‐related protein‐2 (MTMR2) or its regulatory binding partner MTMR13/SBF2. Mtmr2 dephosphorylates PI‐3‐P and PI‐3,5‐P2 to form phosphatidylinositol and PI‐5‐P, respectively, while Mtmr13/Sbf2 is an enzymatically inactive member of the myotubularin protein family. We have found altered levels of the critical signalling protein AKT in mouse mutants for Mtmr2 and Mtmr13/Sbf2. Thus, we analysed the influence of Mtmr2 and Mtmr13/Sbf2 on signalling processes. We found that overexpression of Mtmr2 prevents the degradation of the epidermal growth factor receptor (EGFR) and leads to sustained Akt activation whereas Erk activation is not affected. Mtmr13/Sbf2 counteracts the blockage of EGFR degradation without affecting prolonged Akt activation. Our data indicate that Mtmr2 and Mtmr13/Sbf2 play critical roles in the sorting and modulation of cellular signalling which are likely to be disturbed in CMT4B.     

Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatidylinositol 3-phosphatases

Phosphoinositides control many different processes required for normal cellular function. Myotubularins are a family of Phosphatidylinositol 3-phosphate (PtdIns3P) phosphatases identified by the positional cloning of the MTM1 gene in patients suffering from X-linked myotubular myopathy and the MTMR2 gene in patients suffering from the demyelinating neuropathy Charcot-Marie-Tooth disease type 4B. MTM1 is a phosphatidylinositol phosphatase with reported specificity toward PtdIns3P, while the related proteins MTMR2 and MTMR3 hydrolyze both PtdIns3P and PtdIns(3,5)P2. We have investigated MTM1 and MTMR6 and find that they use PtdIns(3,5)P2 in addition to PtdIns3P as a substrate in vitro. The product of PtdIns(3,5)P2 hydrolysis, PtdIns5P, causes MTM1 to form a heptameric ring that is 12.5 nm in diameter, and it is a specific allosteric activator of MTM1, MTMR3, and MTMR6. A disease-causing mutation at arginine 69 of MTM1 falling within a putative pleckstrin homology domain reduces the ability of the enzyme to respond to PtdIns5P. We propose that the myotubularin family of enzymes utilize both PtdIns3P and PtdIns(3,5)P2 as substrates, and that PtdIns5P functions in a positive feedback loop controlling their activity. These findings highlight the importance of regulated phosphatase activity for the control of phosphoinositide metabolism.     

PI(3,5)P2 controls endosomal branched actin dynamics by regulating cortactin–actin interactions

Branched actin critically contributes to membrane trafficking by regulating membrane curvature, dynamics, fission, and transport. However, how actin dynamics are controlled at membranes is poorly understood. Here, we identify the branched actin regulator cortactin as a direct binding partner of phosphatidylinositol 3,5-bisphosphate (PI(3,5)P₂) and demonstrate that their interaction promotes turnover of late endosomal actin. In vitro biochemical studies indicated that cortactin binds PI(3,5)P₂ via its actin filament-binding region. Furthermore, PI(3,5)P₂ competed with actin filaments for binding to cortactin, thereby antagonizing cortactin activity. These findings suggest that PI(3,5)P₂ formation on endosomes may remove cortactin from endosome-associated branched actin. Indeed, inhibition of PI(3,5)P₂ production led to cortactin accumulation and actin stabilization on Rab7⁺ endosomes. Conversely, inhibition of Arp2/3 complex activity greatly reduced cortactin localization to late endosomes. Knockdown of cortactin reversed PI(3,5)P₂-inhibitor–induced actin accumulation and stabilization on endosomes. These data suggest a model in which PI(3,5)P₂ binding removes cortactin from late endosomal branched actin networks and thereby promotes net actin turnover.     

Sequential actions of myotubularin lipid phosphatases regulate endosomal PI(3)P and growth factor receptor trafficking

Two different human diseases, X-linked myotubular myopathy and Charcot-Marie-Tooth disease, result from mutant MTM1 or MTMR2 lipid phosphatases. Although events involved in endosomal PI(3)P and PI(3,5)P(2) synthesis are well established and pivotal in receptor signaling and degradation, enzymes involved in phosphoinositide degradation and their roles in trafficking are incompletely characterized. Here, we dissect the functions of the MTM1 and MTMR2 myotubularins and establish how they contribute to endosomal PI(3)P homeostasis. By mimicking loss of function in disease through siRNA-mediated depletion of the myotubularins, excess PI(3)P accumulates on early (MTM1) and late (MTMR2) endosomes. Surprisingly, the increased PI(3)P blocks the egress of epidermal growth factor receptors from early or late endosomes, suggesting that the accumulation of signaling receptors in distinct endosomes may contribute to the unique disease etiologies when MTM1 or MTMR2 are mutant. We further demonstrate that direct myotubularin binding to the type III PI 3-kinase complex hVps34/hVps15 leads to phosphatase inactivation. The lipid kinase-phosphatase interaction also precludes interaction of the PI 3-kinase with Rab GTPase activators. Thus, unique molecular complexes control kinase and phosphatase activation and locally regulate PI(3)P on discrete endosome populations, thereby providing a molecular rationale for related human myo- and neuropathies.     

The phosphatidylinositol 3-phosphate phosphatase myotubularin- related protein 6 (MTMR6) is a negative regulator of the Ca2+-activated K+ channel KCa3.1

Myotubularins (MTMs) belong to a large subfamily of phosphatases that dephosphorylate the 3' position of phosphatidylinositol 3-phosphate [PI(3)P] and PI(3,5)P(2). MTM1 is mutated in X-linked myotubular myopathy, and MTMR2 and MTMR13 are mutated in Charcot-Marie-Tooth syndrome. However, little is known about the general mechanism(s) whereby MTMs are regulated or the specific biological processes regulated by the different MTMs. We identified a Ca(2+)-activated K channel, K(Ca)3.1 (also known as KCa4, IKCa1, hIK1, or SK4), that specifically interacts with the MTMR6 subfamily of MTMs via coiled coil (CC) domains on both proteins. Overexpression of MTMR6 inhibited K(Ca)3.1 channel activity, and this inhibition required MTMR6's CC and phosphatase domains. This inhibition is specific; MTM1, a closely related MTM, did not inhibit K(Ca)3.1. However, a chimeric MTM1 in which the MTM1 CC domain was swapped for the MTMR6 CC domain inhibited K(Ca)3.1, indicating that MTM CC domains are sufficient to confer target specificity. K(Ca)3.1 was also inhibited by the PI(3) kinase inhibitors LY294002 and wortmannin, and this inhibition was rescued by the addition of PI(3)P, but not other phosphoinositides, to the patch pipette solution. PI(3)P also rescued the inhibition of K(Ca)3.1 by MTMR6 overexpression. These data, when taken together, indicate that K(Ca)3.1 is regulated by PI(3)P and that MTMR6 inhibits K(Ca)3.1 by dephosphorylating the 3' position of PI(3)P, possibly leading to decreased PI(3)P in lipid microdomains adjacent to K(Ca)3.1. K(Ca)3.1 plays important roles in controlling proliferation by T cells, vascular smooth muscle cells, and some cancer cell lines. Thus, our findings not only provide unique insights into the regulation of K(Ca)3.1 channel activity but also raise the possibility that MTMs play important roles in the negative regulation of T cells and in conditions associated with pathological cell proliferation, such as cancer and atherosclerosis.     

Host PI(3,5)P2 Activity Is Required for Plasmodium berghei Growth During Liver Stage Infection

Malaria parasites go through an obligatory liver stage before they infect erythrocytes and cause disease symptoms. In the host hepatocytes, the parasite is enclosed by a parasitophorous vacuole membrane (PVM). Here, we dissected the interaction between the Plasmodium parasite and the host cell late endocytic pathway and show that parasite growth is dependent on the phosphoinositide 5‐kinase (PIKfyve) that converts phosphatidylinositol 3‐phosphate [PI(3)P] into phosphatidylinositol 3,5‐bisphosphate [PI(3,5)P₂] in the endosomal system. We found that inhibition of PIKfyve by either pharmacological or non‐pharmacological means causes a delay in parasite growth. Moreover, we show that the PI(3,5)P₂ effector protein TRPML1 that is involved in late endocytic membrane fusion, is present in vesicles closely contacting the PVM and is necessary for parasite growth. Thus, our studies suggest that the parasite PVM is able to fuse with host late endocytic vesicles in a PI(3,5)P₂‐dependent manner, allowing the exchange of material between the host and the parasite, which is essential for successful infection.      

Overexpression of FAB1A-GFP recruits SNX2b on the endosome membrane in snx1–1 mutant in Arabidopsis

Phosphatidylinositol 3,5-bisphosphate [PI(3,5)P₂] is one of the phosphoinositides that controls endosomal trafficking events in eukaryotes. PtdIns(3,5)P₂ is produced from PI(3)P by phosphatidylinositol 3-phosphate 5-kinase FAB1/PIKfyve. Recently, we reported that FAB1 predominantly localizes on the SNX1-residing late endosomes and a loss-of FAB1 function causes the release of late endosomal effector proteins, ARA7/RABF2b and SORTING NEXIN 1 from the endosome membrane, indicating that FAB1 or its product PtdIns(3,5)P₂ mediates the maturation process of the late endosomes. Intriguingly, the ectopic expression of FAB1A could complement the sucrose-dependent seedling growth phenotype of snx1–1 mutant. Here, we demonstrated that the depletion of SNX1 causes the release of SNX2b-mRFP from the endosomal membrane. However, overexpression of FAB1A-GFP reassembles SNX2b-mRFP on the endosomal membrane despite the absence of SNX1. From these results, we proposed that SNX2b homodimer or SNX2a/SNX2b heterodimer might function as functional Sorting Nexin complex instead of SNX1 to attach the endosomal membrane by binding of overproduced PI(3,5)P₂ in Arabidopsis.     

Specificity of the myotubularin family of phosphatidylinositol-3-phosphatase is determined by the PH/GRAM domain

Myotubularins (MTM) are a large subfamily of lipid phosphatases that specifically dephosphorylate at the D3 position of phosphatidylinositol 3-phosphate (PI(3)P) in PI(3)P and PI(3,5)P2. We recently found that MTMR6 specifically inhibits the Ca2+-activated K+ channel, KCa3.1, by dephosphorylating PI(3)P. We now show that inhibition is specific for MTMR6 and other MTMs do not inhibit KCa3.1. By replacing either or both of the coiled-coil (CC) and pleckstrin homology/GRAM (PH/G) domains of MTMs that failed to inhibit KCa3.1 with the CC and PH/G domains of MTMR6, we found that chimeric MTMs containing both the MTMR6 CC and PH/G domains functioned like MTMR6 to inhibit KCa3.1 channel activity, whereas chimeric MTMs containing either domain alone did not. Immunofluorescent microscopy demonstrated that both the MTMR6 CC and PH/G domains are required to co-localize MTMR6 to the plasma membrane with KCa3.1. These findings support a model in which two specific low affinity interactions are required to co-localize MTMR6 with KCa3.1: 1) between the CC domains on MTMR6 and KCa3.1 and (2) between the PH/G domain and a component of the plasma membrane. Our inability to detect significant interaction of the MTMR6 G/PH domain with phosphoinositides suggests that this domain may bind a protein. Identifying the specific binding partners of the CC and PH/G domains on other MTMs will provide important clues to the specific functions regulated by other MTMs as well as the mechanism(s) whereby loss of some MTMs lead to disease.     

Phosphatidylinositol 3,5‐bisphosphate regulates Ca2+ transport during yeast vacuolar fusion through the Ca2+ ATPase Pmc1

The transport of Ca²⁺ across membranes precedes the fusion and fission of various lipid bilayers. Yeast vacuoles under hyperosmotic stress become fragmented through fission events that requires the release of Ca²⁺ stores through the TRP channel Yvc1. This requires the phosphorylation of phosphatidylinositol‐3‐phosphate (PI3P) by the PI3P‐5‐kinase Fab1 to produce transient PI(3,5)P₂ pools. Ca²⁺ is also released during vacuole fusion upon trans‐SNARE complex assembly, however, its role remains unclear. The effect of PI(3,5)P₂ on Ca²⁺ flux during fusion was independent of Yvc1. Here, we show that while low levels of PI(3,5)P₂ were required for Ca²⁺ uptake into the vacuole, increased concentrations abolished Ca²⁺ efflux. This was as shown by the addition of exogenous dioctanoyl PI(3,5)P₂ or increased endogenous production of by the hyperactive fab1^T2250A mutant. In contrast, the lack of PI(3,5)P₂ on vacuoles from the kinase dead fab1^EEE mutant showed delayed and decreased Ca²⁺ uptake. The effects of PI(3,5)P₂ were linked to the Ca²⁺ pump Pmc1, as its deletion rendered vacuoles resistant to the effects of excess PI(3,5)P₂. Experiments with Verapamil inhibited Ca²⁺ uptake when added at the start of the assay, while adding it after Ca²⁺ had been taken up resulted in the rapid expulsion of Ca²⁺. Vacuoles lacking both Pmc1 and the H⁺/Ca²⁺ exchanger Vcx1 lacked the ability to take up Ca²⁺ and instead expelled it upon the addition of ATP. Together these data suggest that a balance of efflux and uptake compete during the fusion pathway and that the levels of PI(3,5)P₂ can modulate which path predominates.     

Lipid kinases are essential for apicoplast homeostasis in Toxoplasma gondii

Phosphoinositides regulate numerous cellular processes by recruiting cytosolic effector proteins and acting as membrane signalling entities. The cellular metabolism and localization of phosphoinositides are tightly regulated by distinct lipid kinases and phosphatases. Here, we identify and characterize a unique phosphatidylinositol 3 kinase (PI3K) in Toxoplasma gondii, a protozoan parasite belonging to the phylum Apicomplexa. Conditional depletion of this enzyme and subsequently of its product, PI(3)P, drastically alters the morphology and inheritance of the apicoplast, an endosymbiotic organelle of algal origin that is a unique feature of many Apicomplexa. We searched the T. gondii genome for PI(3)P‐binding proteins and identified in total six PX and FYVE domain‐containing proteins including a PIKfyve lipid kinase, which phosphorylates PI(3)P into PI(3,5)P₂. Although depletion of putative PI(3)P‐binding proteins shows that they are not essential for parasite growth and apicoplast biology, conditional disruption of PIKfyve induces enlarged apicoplasts, as observed upon loss of PI(3)P. A similar defect of apicoplast homeostasis was also observed by knocking down the PIKfyve regulatory protein ArPIKfyve, suggesting that in T. gondii, PI(3)P‐related function for the apicoplast might mainly be to serve as a precursor for the synthesis of PI(3,5)P₂. Accordingly, PI3K is conserved in all apicomplexan parasites whereas PIKfyve and ArPIKfyve are absent in Cryptosporidium species that lack an apicoplast, supporting a direct role of PI(3,5)P₂ in apicoplast homeostasis. This study enriches the already diverse functions attributed to PI(3,5)P₂ in eukaryotic cells and highlights these parasite lipid kinases as potential drug targets.     

Receptor mediated endocytosis 8 is a novel PI(3)P binding protein regulated by myotubularin-related 2

Myotubularin related protein 2 (MTMR2) is a member of the myotubularin family of phosphoinositide lipid phosphatases. Although MTMR2 dephosphorylates the phosphoinositides PI(3)P and PI(3,5)P2, the phosphoinositide binding proteins that are regulated by MTMR2 are poorly characterized. In this study, phosphoinositide affinity chromatography coupled to mass spectrometry identified receptor mediated endocytosis 8 (RME-8) as a novel PI(3)P binding protein. RME-8 co-localized with the PI(3)P marker DsRed-FYVE, while the N-terminal region of RME-8 is required for PI(3)P and PI(3,5)P(2) binding in vitro. Depletion of PI(3)P by MTMR2 S58A or wortmannin treatment attenuated RME-8 endosomal localization and co-localization with EGFR on early endosomes. Our results suggest a model in which the localization of RME-8 to endosomal compartments is spatially mediated by PI(3)P binding and temporally regulated by MTMR2 activity.     

Perturbation of the Vacuolar ATPase: A NOVEL CONSEQUENCE OF INOSITOL DEPLETION*

Depletion of inositol has profound effects on cell function and has been implicated in the therapeutic effects of drugs used to treat epilepsy and bipolar disorder. We have previously shown that the anticonvulsant drug valproate (VPA) depletes inositol by inhibiting myo-inositol-3-phosphate synthase, the enzyme that catalyzes the first and rate-limiting step of inositol biosynthesis. To elucidate the cellular consequences of inositol depletion, we screened the yeast deletion collection for VPA-sensitive mutants and identified mutants in vacuolar sorting and the vacuolar ATPase (V-ATPase). Inositol depletion caused by starvation of ino1Δ cells perturbed the vacuolar structure and decreased V-ATPase activity and proton pumping in isolated vacuolar vesicles. VPA compromised the dynamics of phosphatidylinositol 3,5-bisphosphate (PI3,5P₂) and greatly reduced V-ATPase proton transport in inositol-deprived wild-type cells. Osmotic stress, known to increase PI3,5P₂ levels, did not restore PI3,5P₂ homeostasis nor did it induce vacuolar fragmentation in VPA-treated cells, suggesting that perturbation of the V-ATPase is a consequence of altered PI3,5P₂ homeostasis under inositol-limiting conditions. This study is the first to demonstrate that inositol depletion caused by starvation of an inositol synthesis mutant or by the inositol-depleting drug VPA leads to perturbation of the V-ATPase.     

Production of phosphatidylinositol 5‐phosphate via PIKfyve and MTMR3 regulates cell migration

Although phosphatidylinositol 5‐phosphate (PtdIns5P) is present in many cell types and its biogenesis is increased by diverse stimuli, its precise cellular function remains elusive. Here we show that PtdIns5P levels increase when cells are stimulated to move and we find PtdIns5P to promote cell migration in tissue culture and in a Drosophila in vivo model. First, class III phosphatidylinositol 3‐kinase, which produces PtdIns3P, was shown to be involved in migration of fibroblasts. In a cell migration screen for proteins containing PtdIns3P‐binding motifs, we identified the phosphoinositide 5‐kinase PIKfyve and the phosphoinositide 3‐phosphatase MTMR3, which together constitute a phosphoinositide loop that produces PtdIns5P via PtdIns(3,5)P₂. The ability of PtdIns5P to stimulate cell migration was demonstrated directly with exogenous PtdIns5P and a PtdIns5P‐producing bacterial enzyme. Thus, the identified phosphoinositide loop defines a new role for PtdIns5P in cell migration.     

VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P2 in yeast and mouse

The signalling lipid PI(3,5)P₂ is generated on endosomes and regulates retrograde traffic to the trans‐Golgi network. Physiological signals regulate rapid, transient changes in PI(3,5)P₂ levels. Mutations that lower PI(3,5)P₂ cause neurodegeneration in human patients and mice. The function of Vac14 in the regulation of PI(3,5)P₂ was uncharacterized previously. Here, we predict that yeast and mammalian Vac14 are composed entirely of HEAT repeats and demonstrate that Vac14 exerts an effect as a scaffold for the PI(3,5)P₂ regulatory complex by direct contact with the known regulators of PI(3,5)P₂: Fig4, Fab1, Vac7 and Atg18. We also report that the mouse mutant ingls (in fantile gl ios is) results from a missense mutation in Vac14 that prevents the association of Vac14 with Fab1, generating a partial complex. Analysis of ingls and two additional mutants provides insight into the organization of the PI(3,5)P₂ regulatory complex and indicates that Vac14 mediates three distinct mechanisms for the rapid interconversion of PI3P and PI(3,5)P₂. Moreover, these studies show that the association of Fab1 with the complex is essential for viability in the mouse.     

A role for eisosomes in maintenance of plasma membrane phosphoinositide levels

The plasma membrane delineates the cell and mediates its communication and material exchange with the environment. Many processes of the plasma membrane occur through interactions of proteins with phosphatidylinositol(4,5)-bisphosphate (PI(4,5)P₂), which is highly enriched in this membrane and is a key determinant of its identity. Eisosomes function in lateral organization of the plasma membrane, but the molecular function of their major protein subunits, the BAR domain–containing proteins Pil1 and Lsp1, is poorly understood. Here we show that eisosomes interact with the PI(4,5)P₂ phosphatase Inp51/Sjl1, thereby recruiting it to the plasma membrane. Pil1 is essential for plasma membrane localization and function of Inp51 but not for the homologous phosphatidylinositol bisphosphate phosphatases Inp52/Sjl2 and Inp53/Sjl3. Consistent with this, absence of Pil1 increases total and available PI(4,5)P₂ levels at the plasma membrane. On the basis of these findings, we propose a model in which the eisosomes function in maintaining PI(4,5)P₂ levels by Inp51/Sjl1 recruitment.     

PIKfyve-ArPIKfyve-Sac3 Core Complex: CONTACT SITES AND THEIR CONSEQUENCE FOR Sac3 PHOSPHATASE ACTIVITY AND ENDOCYTIC MEMBRANE HOMEOSTASIS*

The phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P₂) metabolizing enzymes, the kinase PIKfyve and the phosphatase Sac3, constitute a single multiprotein complex organized by the PIKfyve regulator ArPIKfyve and its ability to homodimerize. We previously established that PIKfyve is activated within the triple PIKfyve-ArPIKfyve-Sac3 (PAS) core. These data assign an atypical function for the phosphatase in PtdIns(3,5)P₂ biosynthesis, thus raising the question of whether Sac3 retains its PtdIns(3,5)P₂ hydrolyzing activity within the PAS complex. Herein, we address the issue of Sac3 functionality by a combination of biochemical and morphological assays in triple-transfected COS cells using a battery of truncated or point mutants of the three proteins. We identified the Cpn60_TCP1 domain of PIKfyve as a major determinant for associating the ArPIKfyve-Sac3 subcomplex. Neither Sac3 nor PIKfyve enzymatic activities affected the PAS complex formation or stability. Using the well established formation of aberrant cell vacuoles as a sensitive functional measure of localized PtdIns(3,5)P₂ reduction, we observed a mitigated vacuolar phenotype by kinase-deficient PIKfyve^K1831E if its ArPIKfyve-Sac3 binding region was deleted, suggesting reduced Sac3 access to, and turnover of PtdIns(3,5)P₂. In contrast, PIKfyve^K1831E, which displays intact ArPIKfyve-Sac3 binding, triggered a more severe vacuolar phenotype if coexpressed with ArPIKfyve^WT-Sac3^WT but minimal defects when coexpressed with ArPIKfyve^WT and phosphatase-deficient Sac3^D488A. These data indicate that Sac3 assembled in the PAS regulatory core complex is an active PtdIns(3,5)P₂ phosphatase. Based on these and other data, presented herein, we propose a model of domain interactions within the PAS core and their role in regulating the enzymatic activities.